E. Sherman

M. Millenson, S. Litwin, S. Feigenberg, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Combined high‐intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base

M. Luu, N. Lee, A. Ho, 2017, Cancer.

A nomogram to predict loco-regional control after re-irradiation for head and neck cancer.

Julian C. Hong, N. Lee, L. Morris, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Trends and Disparities of Proton Therapy Use among Patients with Head and Neck Cancer: Analysis from the National Cancer Database (2005-14).

N. Lee, N. Riaz, S. McBride, 2019, International journal of particle therapy.

Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab

E. Elkin, N. Lee, S. Baxi, 2016, Head & neck.

Using patients as their own controls for cost evaluation of phase I clinical trials.

E. Venkatraman, V. Miller, G. Schwartz, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity‐modulated radiotherapy era

N. Lee, A. Ho, S. Baxi, 2017, Cancer.

Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus-Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy.

N. Lee, R. Wong, N. Riaz, 2022, JAMA oncology.

Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer

N. Lee, D. Pfister, N. Riaz, 2020, International journal of cancer.

Head and neck cancers associated with exposure to the September 11, 2001 World Trade Center terrorist attacks

N. Lee, R. Wong, N. Riaz, 2018, International journal of cancer.

Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck

W. Shi, N. Lee, N. Katabi, 2016, American journal of clinical oncology.

Definitive chemoradiation for primary oral cavity carcinoma: A single institution experience.

N. Lee, R. Wong, N. Riaz, 2015, Oral oncology.

Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC).

W. Shi, N. Lee, D. Pfister, 2014, Oral oncology.

Patients with low lying lymph nodes are at high risk for distant metastasis in oropharyngeal cancer.

N. Lee, R. Wong, N. Riaz, 2014, Oral oncology.

A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

N. Katabi, A. Ho, D. Pfister, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies

L. Weiner, M. Mehren, R. Knoblauch, 2015, Cancer Chemotherapy and Pharmacology.

A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer

C. Sima, A. Heguy, N. Katabi, 2013, Cancer.

Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma.

D. Pfister, H. Schöder, R. Ghossein, 2013, Thyroid : official journal of the American Thyroid Association.

A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)

C. Sima, N. Katabi, A. Ho, 2012, Cancer Chemotherapy and Pharmacology.

A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors

R. Shen, D. Pfister, E. Sherman, 2012, Cancer Chemotherapy and Pharmacology.

Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy

M. Millenson, H. Borghaei, C. Langer, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Characteristics of cancer patients entering a smoking cessation program and correlates of quit motivation: implications for the development of tobacco control programs for cancer patients

Suzanne M. Miller, C. Lerman, B. Movsas, 2004, Psycho-oncology.

Comparing cancer patients who enroll in a smoking cessation program at a comprehensive cancer center with those who decline enrollment

Suzanne M. Miller, C. Lerman, B. Movsas, 2004, Head & neck.

Employment and return to work following chemoradiation in patient with HPV-related oropharyngeal cancer

E. Elkin, N. Lee, S. Baxi, 2016, Cancers of the Head & Neck.

Combined modality treatment of squamous cell cancer of the head and neck.

E. Sherman, J. Devlin, 2005, Clinical advances in hematology & oncology : H&O.

A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC).

A. Garden, K. Ang, R. Weber, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hemorrhagic pseudoaneurysm in a patient receiving aflibercept for metastatic thyroid cancer.

K. Brown, S. Baxi, D. Pfister, 2012, Thyroid : official journal of the American Thyroid Association.

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.

V. Seshan, S. Larson, S. Baxi, 2018, The Journal of clinical endocrinology and metabolism.

Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6–NTRK3 fusion

J. Shah, S. Dogan, N. Katabi, 2016, Modern Pathology.

Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease‐specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy

R. Tuttle, E. Sherman, M. Sabra, 2019, Clinical endocrinology.

Any day, split halfway: Flexibility in scheduling high‐dose cisplatin—A large retrospective review from a high‐volume cancer center

N. Lee, I. Ganly, Bhuvanesh Singh, 2021, International journal of cancer.

Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer

S. Baxi, A. Ho, D. Pfister, 2019, Cancer.

Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease.

N. Lee, R. Wong, N. Riaz, 2018, Thyroid : official journal of the American Thyroid Association.

Structural doubling time predicts overall survival in patients with medullary thyroid cancer in patients with rapidly progressive metastatic medullary thyroid cancer treated with molecular targeted therapies.

R. Tuttle, E. Sherman, M. Sabra, 2020, Thyroid : official journal of the American Thyroid Association.

Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.

N. Lee, S. Baxi, A. Ho, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

G. Shapiro, C. Peterfy, I. Puzanov, 2021, Clinical Cancer Research.

Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy

N. Lee, R. Wong, R. Tuttle, 2022, International journal of particle therapy.

Registrational results of LOXO-292 in patients with RET-altered thyroid cancers

A. Drilon, T. Owonikoko, B. Solomon, 2019, Annals of Oncology.

Should cetuximab replace Cisplatin for definitive chemoradiotherapy in locally advanced head and neck cancer?

N. Lee, N. Riaz, E. Sherman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers.

N. Lee, I. Ganly, Bhuvanesh Singh, 2020, Oral oncology.

Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.

C. Antonescu, I. Ostrovnaya, N. Katabi, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.

N. Agarwal, D. Pfister, R. Mehra, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg / m 2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

N. Agarwal, D. Pfister, R. Mehra, 2012 .

Phase II study of bevacizumab (B) plus cisplatin (C) plus intensity-modulated radiation therapy (IMRT) for locoregionally advanced head and neck squamous cell cancer (HNSCC): Preliminary results.

J. Shah, R. Shen, D. Kraus, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

A. Drilon, M. Burkard, T. Owonikoko, 2020, The New England journal of medicine.

Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus‐associated oropharyngeal cancer

N. Lee, I. Ganly, Bhuvanesh Singh, 2022, CA: a cancer journal for clinicians.

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.

E. Vokes, P. Bycott, L. Rosen, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes for Organ Preservation with Chemoradiation Therapy for T4 Larynx and Hypopharynx Cancer

N. Lee, R. Wong, J. Cracchiolo, 2022, The Laryngoscope.

A New Intensified Therapeutic Regimen for Advanced Head and Neck Squamous Cell Carcinomas: Where Does It Fit Among Available Treatment Options?

D. Pfister, S. Wolden, E. Sherman, 2001, Cancer investigation.

Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base

C. Brennan, N. Lee, I. Ganly, 2020, International journal of particle therapy.

Treatment modalities and outcomes of Fanconi anemia patients with head and neck squamous cell carcinoma: Series of 9 cases and review of the literature

N. Lee, Bhuvanesh Singh, N. Riaz, 2019, Head & neck.

Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy

N. Lee, I. Ganly, Bhuvanesh Singh, 2022, JAMA network open.

Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy

N. Lee, N. Riaz, D. Mah, 2021, JAMA network open.

Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot

N. Lee, J. Zong, N. Riaz, 2018, International journal of particle therapy.

Preliminary evaluation of response to combination of RAD001 and cetuximab using [18F]-fluorodeoxyglucose positron emission tomography (18FDG-PET)

K. Flaherty, P. O'dwyer, C. Divgi, 2008 .

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer

M. Brose, R. Elisei, L. Wirth, 2022, Future oncology.

TALK score: Development and validation of a prognostic model for predicting larynx preservation outcome

V. Seshan, J. Shah, M. Zelefsky, 2012, The Laryngoscope.

Proton therapy for head and neck cancer: expanding the therapeutic window.

Nadeem Riaz, Nancy Lee, Sean McBride, 2017, The Lancet. Oncology.

Relief of Feedback Inhibition of Her3 Transcription by Raf and Mek Inhibitors Attenuates Their Antitumor Effects in Braf -mutant Thyroid Carcinomas Human Oncology and Pathogenesis Program, Pathology, And

A. Viale, N. Rosen, J. Fagin, 2022 .

Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review.

A. Ho, D. Pfister, E. Sherman, 2011, The Lancet. Oncology.

Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404)

N. Foster, G. Schwartz, N. Katabi, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma.

C. Antonescu, T. Chan, N. Katabi, 2016 .

The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform

M. Berger, J. Shah, T. Chan, 2017, JAMA oncology.

A Phase Ib Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity-Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.

N. Lee, N. Katabi, S. Baxi, 2020, International journal of radiation oncology, biology, physics.

A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.

C. Antonescu, S. Dogan, N. Katabi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma.

N. Socci, A. Viale, J. Shah, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent.

J. Shah, E. Venkatraman, M. Zelefsky, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival in patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed therapy

N. Lee, N. Riaz, D. Goldman, 2019, British Journal of Cancer.

TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence

S. Dogan, N. Lee, N. Katabi, 2021, JCO precision oncology.

Prediction of survival in patients with head and neck cancer using the histoculture drug response assay

J. Shah, Bhuvanesh Singh, D. Pfister, 2002, Head & neck.

Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases.

Jason A Koutcher, Amita Shukla-Dave, Sasan Karimi, 2012, International journal of radiation oncology, biology, physics.

Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques

N. Lee, N. Riaz, Z. Zumsteg, 2017, JAMA oncology.

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

M. Brose, S. Sherman, L. Wirth, 2016, The Lancet. Oncology.

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

S. Larson, R. Shen, J. Ricarte-Filho, 2013, The New England journal of medicine.

Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma.

John Humm, Nadeem Riaz, Nancy Lee, 2016, International journal of radiation oncology, biology, physics.

Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial.

Lydia Y. Liu, Takafumi N. Yamaguchi, J. Humm, 2021, Journal of the National Cancer Institute.

Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.

J. Shah, M. Zelefsky, D. Kraus, 2011, International journal of radiation oncology, biology, physics.

Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus‐associated oropharyngeal squamous cell cancer

N. Katabi, D. Pfister, E. Sherman, 2018, Head & neck.

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

A. Drilon, Keunchil Park, S. Leyvraz, 2022, European journal of endocrinology.

Pazopanib Enhances Paclitaxel-Induced Mitotic Catastrophe in Anaplastic Thyroid Cancer

J. Copland, R. Smallridge, Rakesh Kumar, 2013, Science Translational Medicine.

Targeting VEGF and EGFR: a combination worth re-exploring?

E. Sherman, V. Tchekmedyian, 2018, The Lancet. Oncology.

Anaplastic Thyroid Cancer Pazopanib Enhances Paclitaxel-Induced Mitotic Catastrophe in

J. Copland, R. Smallridge, Rakesh Kumar, 2012 .

Long‐term outcomes in oral cavity squamous cell carcinoma with adjuvant and salvage radiotherapy after surgery

W. Shi, N. Lee, I. Ganly, 2018, The Laryngoscope.

Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy

T. Chan, S. Dogan, A. Ho, 2021, Molecular Cancer Research.

Dissecting Anaplastic Thyroid Carcinoma (ATC): A Comprehensive Clinical, histologic, Immunophenotypic, and Molecular Study of 360 Cases.

S. Dogan, N. Katabi, A. Gill, 2020, Thyroid : official journal of the American Thyroid Association.

Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM

T. Chan, N. Lee, I. Ganly, 2016, Oncotarget.

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes

M. Schlumberger, S. Sherman, R. Haddad, 2017, Endocrine.

Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer

N. Lee, I. Ganly, N. Riaz, 2020, Cancer.

Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review.

N. Lee, M. Rivera, O. Lin, 2011, Radiotherapy and Oncology.

The 3 Bs of cancer care amid the COVID‐19 pandemic crisis: “Be safe, be smart, be kind”—A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer

J. Shah, N. Lee, I. Ganly, 2020, Cancer.

Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase.

A. Drilon, C. Rudin, J. Fagin, 2022, JCO precision oncology.

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

C. Bourque, B. Taylor, M. Ladanyi, 2022, Nature Communications.

GRADING OF MEDULLARY THYROID CARCINOMA ON THE BASIS OF TUMOR NECROSIS AND HIGH MITOTIC RATE IS AN INDEPENDENT PREDICTOR OF POOR OUTCOME

P. Spanheimer, S. Dogan, I. Ganly, 2020, Modern Pathology.

Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.

V. Seshan, S. Larson, S. Baxi, 2022, Thyroid : official journal of the American Thyroid Association.

Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).

R. Shen, N. Lee, B. Mueller, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

E. Elkin, N. Lee, S. Baxi, 2015, Cancer.

Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer.

A. Ho, E. Sherman, 2011, Clinical advances in hematology & oncology : H&O.

Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers.

N. Lee, N. Riaz, R. Lanning, 2015, Oral oncology.

Clinical economics of head and neck malignancies.

D. Pfister, E. Sherman, H. Ruchlin, 1999, Hematology/oncology clinics of North America.

Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity‐modulated radiotherapy with concurrent chemotherapy

D. Kraus, N. Lee, N. Riaz, 2012, Cancer.

Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.

M. Lacouture, E. Sherman, Shenhong Wu, 2012, The Journal of clinical endocrinology and metabolism.

Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients.

M. Millenson, C. Langer, J. Babb, 2002, Clinical lung cancer.

Biological Features of Human Papillomavirus-related Head and Neck Cancers Contributing to Improved Response.

N. Lee, N. Katabi, N. Riaz, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

The collection of indirect and nonmedical direct costs (COIN) form

H. Scher, S. Slovin, W. Kelly, 2001, Cancer.

Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes.

J. Shah, M. Zelefsky, D. Kraus, 2012, International journal of radiation oncology, biology, physics.

Long‐term quality of life in older patients with HPV‐related oropharyngeal cancer

E. Elkin, N. Lee, S. Baxi, 2018, Head & neck.

Hypopharyngeal squamous cell carcinoma: Three‐dimensional or Intensity‐modulated radiotherapy? A single institution's experience

N. Lee, N. Riaz, S. McBride, 2016, The Laryngoscope.

Phase Ib study of cetuximab + BYL719 + IMRT in stage III-IVB head and neck squamous cell carcinoma (HNSCC).

N. Lee, N. Katabi, S. Baxi, 2017 .

Cisplatin (CDDP) and Radiation (RT) versus Cetuximab (C) and RT in the Context of Human Papillomavirus (HPV) and P16 in the Treatment of Locally Advanced Head and Neck Cancer (LAHNC)

N. Lee, N. Katabi, D. Pfister, 2010 .

Intensity‐modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial

N. Lee, I. Ganly, R. Wong, 2021, Cancer.

Target volume delineation in oropharyngeal cancer: impact of PET, MRI, and physical examination.

N. Lee, R. Wong, H. Schöder, 2010, International journal of radiation oncology, biology, physics.

Impact of concomitant chemoradiation on survival for patients with T1‐2N1 head and neck cancer

N. Lee, A. Ho, Z. Zumsteg, 2017, Cancer.

The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [(18)F] fluorodeoxyglucose positron emission tomography scan.

N. Lee, D. Spratt, N. Riaz, 2014, Oral oncology.

Sharing a diagnosis of HPV‐related head and neck cancer: The emotions, the confusion, and what patients want to know

E. Elkin, S. Baxi, J. Hay, 2013, Head & neck.

A phase 2 study of bevacizumab with cisplatin plus intensity‐modulated radiation therapy for stage III/IVB head and neck squamous cell cancer

J. Shah, R. Shen, D. Kraus, 2012, Cancer.

A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patients

Suzanne M. Miller, C. Lerman, J. Ridge, 2005, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

Nasopharynx cancer: Induction or adjuvant? That is the question

N. Lee, E. Sherman, 2020, Cancer.

A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer.

J. Shah, R. Shen, A. Heguy, 2013, International journal of radiation oncology, biology, physics.

Clinical Investigation : Head and Neck Cancer A Phase 1 Study of Everolimus D Weekly Cisplatin D Intensity Modulated Radiation Therapy in Head-and-Neck Cancer

J. Shah, R. Shen, A. Heguy, 2022 .

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine‐refractory thyroid cancer

S. Baxi, A. Ho, D. Pfister, 2017, Cancer.

Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial.

N. Foster, B. Haugen, F. Worden, 2020 .

Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell‐derived thyroid carcinoma

R. Tuttle, E. Sherman, M. Sabra, 2017, Cancer.

Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy

N. Lee, R. Wong, N. Riaz, 2021, Head & neck.

Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation.

Shikui Tang, Sean L. Berry, Richard J. Wong, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Pilot study combining PD-L1 antibody durvalumab (D) with CTLA-4 antibody tremelimumab (T) and stereotactic body radiotherapy (SBRT) to treat metastatic anaplastic thyroid cancer (ATC).

N. Lee, A. Ho, D. Pfister, 2019, Journal of Clinical Oncology.

American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

D. Dias-Santagata, Y. Nikiforov, J. Fagin, 2022, Head & neck.

Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer

M. Schlumberger, C. Nutting, K. Bible, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of external beam radiation and targeted therapy in thyroid cancer.

J. Brierley, E. Sherman, 2012, Seminars in radiation oncology.

Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial.

P. Xia, N. Lee, S. Yom, 2023, The Lancet. Oncology.

Biomarker predictors of outcome from a randomized trial of nivolumab +/- stereotactic body radiotherapy (SBRT) in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).

N. Lee, A. Ho, D. Pfister, 2019, Journal of Clinical Oncology.

A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).

N. Lee, S. Baxi, A. Ho, 2018 .

Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity‐modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma

J. Shah, H. Schoder, N. Lee, 2016, Head and Neck.

Post-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity.

N. Lee, I. Ganly, Bhuvanesh Singh, 2023, Oral oncology.

Percutaneous Endoscopic Gastrostomy (PEG) in Oropharyngeal Cancer (OPC) Patients Treated with Intensity Modulated Radiotherapy (IMRT)

D. Kraus, N. Lee, K. Schupak, 2011 .

Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.

C. Langer, E. Sherman, R. Somer, 2008, Clinical lung cancer.

Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma

N. Lee, I. Ganly, Bhuvanesh Singh, 2023, JAMA network open.

The effect of short radiation treatment breaks on chemo‐radiotherapy for oropharyngeal cancers

N. Lee, R. Wong, N. Riaz, 2021, Head & neck.

Prognostic significance of human papillomavirus and Epstein‐Bar virus in nasopharyngeal carcinoma

N. Lee, N. Katabi, N. Riaz, 2019, Head & neck.

Patterns of nodal failure after intensity modulated radiotherapy for nasopharyngeal carcinoma

N. Lee, N. Riaz, J. Setton, 2017, The Laryngoscope.

Primary high‐grade non‐anaplastic thyroid carcinoma: a retrospective study of 364 cases

S. Dogan, I. Ganly, N. Katabi, 2021, Histopathology.

A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer

C. Sima, J. Lyo, A. Ho, 2014, Investigational New Drugs.

Irradiation for locoregionally recurrent, never‐irradiated oral cavity cancers

Julian C. Hong, W. Shi, N. Lee, 2015, Head & neck.

Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).

J. Beck, M. Krahn, E. Sherman, 2005, International journal of radiation oncology, biology, physics.

External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non‐anaplastic non‐medullary thyroid cancer

N. Lee, R. Wong, J. Fagin, 2014, Journal of surgical oncology.

DCE-MRI perfusion imaging of head and neck squamous cell carcinoma nodal metastasis: Identifying radioresistance and the distant metastatic phenotyp

M. Rosen, H. Quon, L. Loevner, 2008 .

Past, present and future of proton therapy for head and neck cancer.

N. Lee, E. Sherman, Marc A. Cohen, 2020, Oral oncology.

The Importance of Locoregional Therapy in Metastatic Nasopharyngeal Cancer.

N. Lee, N. Riaz, E. Sherman, 2020, JAMA oncology.

A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer.

N. Lee, A. Ho, R. Wong, 2022, Thyroid : official journal of the American Thyroid Association.

Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706).

N. Foster, G. Schwartz, I. Ganly, 2021 .

OA 12.07 LOXO-292, a Potent, Highly Selective RET Inhibitor, in MKI-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases

A. Drilon, B. Tuch, V. Velcheti, 2017 .

Phase I study of everolimus (E) plus low-dose weekly cisplatin (C) for patients with advanced solid tumors.

D. Pfister, E. Sherman, M. Fury, 2010 .

Diffusion weighted imaging in predicting progression free survival in patients with squamous cell carcinomas of the head and neck treated with induction chemotherapy.

Sanjeev Chawla, Harry Quon, Harish Poptani, 2011, Academic radiology.

A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic salivary gland cancers (R/M SGCs).

I. Ostrovnaya, A. Ho, D. Pfister, 2021 .

Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity

E. Reznik, I. Ganly, J. Fagin, 2021, Molecular Cancer Therapeutics.

Clinical Outcomes and Toxicities in Oropharyngeal Cancer (OPC) Patients Treated with Proton Therapy: A Single Institutional Experience

Andrew G. Lee, N. Lee, R. Wong, 2020 .

2011 Annual Report

Lotfie A. Yousif, L. A. Yousif, Imad-eldin A. Ali Babiker, 2011 .

Stem cell-like T cell depletion in the recurrent head and neck cancer immune microenvironment

J. Reis-Filho, N. Lee, N. Katabi, 2023, Oncoimmunology.

Association of Low and Intermediate Combined Positive Scores With Outcomes of Treatment With Pembrolizumab in Patients With Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: Secondary Analysis of Keynote 048.

N. Lee, E. Sherman, K. Zakeri, 2022, JAMA oncology.

Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial

I. Ostrovnaya, N. Katabi, A. Ho, 2023, Nature medicine.

2012 Annual Report

S. Seo, H. McArthur, J. Rosenberg, 2012 .

RET-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity

A. Drilon, Soo-Ryum Yang, E. Sherman, 2023, Cancers.

Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.

T. Owonikoko, D. Tan, M. Brose, 2020 .

Phase 1/2 precision medicine study of the next-generation BRAF inhibitor PLX8394.

Sunil Sharma, F. Janku, D. Hong, 2018 .

A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma.

S. Baxi, A. Ho, D. Pfister, 2012 .

HPV cell free DNA as a marker of response to chemoradiation for HPV-positive oropharngeal cancers.

N. Lee, N. Riaz, D. Higginson, 2016 .

Methodologic Concerns in Secondary Analysis of KEYNOTE-048-Reply.

N. Lee, E. Sherman, Yao Yu, 2022, JAMA oncology.

Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer.

S. Baxi, A. Ho, D. Pfister, 2013 .

1914MO Randomized phase II study of radiation therapy and paclitaxel with pazopanib or placebo: NRG-RTOG 0912

P. Xia, C. Chung, N. Lee, 2020 .

Outcomes of surgery and postoperative radiation therapy in managing medullary thyroid carcinoma

N. Lee, R. Wong, J. Plukker, 2019, Journal of surgical oncology.

1656P Durable efficacy of selpercatinib in patients (pts) with medullary thyroid cancer (MTC): Update of the LIBRETTO-001 trial

A. Drilon, L. Wirth, E. Sherman, 2022, Annals of Oncology.

Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer

N. Lee, R. Wong, N. Riaz, 2023, Head & neck.

Patterns of nodal failure after intensity modulated radiotherapy for nasopharyngeal carcinoma

N. Lee, N. Riaz, J. Setton, 2017, The Laryngoscope.

Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.

V. Seshan, E. Reznik, Y. Nikiforov, 2018, Cancer cell.

A. Viale, N. Rosen, J. Fagin, 2022 .

Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.

M. Lacouture, E. Sherman, Shenhong Wu, 2012, The Journal of clinical endocrinology and metabolism.

Transoral robotic surgery: radical tonsillectomy.

G. Weinstein, H. Quon, E. Sherman, 2007, Archives of otolaryngology--head & neck surgery.

Diffusion-WeightedMagnetic Resonance Imaging for Predicting and Detecting Early Response to Chemoradiation Therapy of Squamous Cell Carcinomas of the Head and Neck

G. Weinstein, H. Quon, S. Kim, 2009 .

Long-term update of NRG/RTOG 0522: a randomized phase III trial of concurrent radiation and cisplatin with or without cetuximab in locoregionally advanced head and neck cancer.

A. Garden, R. Weber, J. Galvin, 2022, International journal of radiation oncology, biology, physics.

A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).

I. Ostrovnaya, N. Katabi, A. Ho, 2019, Journal of Clinical Oncology.